In a GBM immunocompromised mouse model, the anti-VEGF aptamer, pegaptanib, reduced GBM blood vessel density and induced tumour hypoxia, but it still allowed the formation of tumour satellites. This evidence concerns the gene VEGFA and glioblastoma.